2555 related articles for article (PubMed ID: 29654196)
1. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Frail Patients With Nonvalvular Atrial Fibrillation.
Martinez BK; Sood NA; Bunz TJ; Coleman CI
J Am Heart Assoc; 2018 Apr; 7(8):. PubMed ID: 29654196
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and Safety of Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin in Patients With Nonvalvular Atrial Fibrillation and Previous Stroke or Transient Ischemic Attack.
Coleman CI; Peacock WF; Bunz TJ; Alberts MJ
Stroke; 2017 Aug; 48(8):2142-2149. PubMed ID: 28655814
[TBL] [Abstract][Full Text] [Related]
3. Effectiveness and Safety of Dabigatran, Rivaroxaban, and Apixaban Versus Warfarin in Nonvalvular Atrial Fibrillation.
Yao X; Abraham NS; Sangaralingham LR; Bellolio MF; McBane RD; Shah ND; Noseworthy PA
J Am Heart Assoc; 2016 Jun; 5(6):. PubMed ID: 27412905
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the Effectiveness and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Newly Diagnosed Atrial Fibrillation.
Hernandez I; Zhang Y; Saba S
Am J Cardiol; 2017 Nov; 120(10):1813-1819. PubMed ID: 28864318
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Apixaban, Dabigatran, Rivaroxaban, and Warfarin in Asians With Nonvalvular Atrial Fibrillation.
Chan YH; See LC; Tu HT; Yeh YH; Chang SH; Wu LS; Lee HF; Wang CL; Kuo CF; Kuo CT
J Am Heart Assoc; 2018 Apr; 7(8):. PubMed ID: 29622587
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness and safety of direct oral anticoagulants compared to warfarin in treatment naïve non-valvular atrial fibrillation patients in the US Department of defense population.
Gupta K; Trocio J; Keshishian A; Zhang Q; Dina O; Mardekian J; Nadkarni A; Shank TC
BMC Cardiovasc Disord; 2019 Jun; 19(1):142. PubMed ID: 31195999
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB
BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243
[No Abstract] [Full Text] [Related]
8. Comparisons between Oral Anticoagulants among Older Nonvalvular Atrial Fibrillation Patients.
Deitelzweig S; Keshishian A; Li X; Kang A; Dhamane AD; Luo X; Balachander N; Rosenblatt L; Mardekian J; Pan X; Nadkarni A; Di Fusco M; Garcia Reeves AB; Yuce H; Lip GYH
J Am Geriatr Soc; 2019 Aug; 67(8):1662-1671. PubMed ID: 31112292
[TBL] [Abstract][Full Text] [Related]
9. Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
Larsen TB; Skjøth F; Nielsen PB; Kjældgaard JN; Lip GY
BMJ; 2016 Jun; 353():i3189. PubMed ID: 27312796
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and Safety of Standard-Dose Nonvitamin K Antagonist Oral Anticoagulants and Warfarin Among Patients With Atrial Fibrillation With a Single Stroke Risk Factor: A Nationwide Cohort Study.
Lip GYH; Skjøth F; Nielsen PB; Kjældgaard JN; Larsen TB
JAMA Cardiol; 2017 Aug; 2(8):872-881. PubMed ID: 28614582
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and Safety of Oral Anticoagulants Among Nonvalvular Atrial Fibrillation Patients.
Lip GYH; Keshishian A; Li X; Hamilton M; Masseria C; Gupta K; Luo X; Mardekian J; Friend K; Nadkarni A; Pan X; Baser O; Deitelzweig S
Stroke; 2018 Dec; 49(12):2933-2944. PubMed ID: 30571400
[TBL] [Abstract][Full Text] [Related]
12. Risk of stroke/systemic embolism, major bleeding and associated costs in non-valvular atrial fibrillation patients who initiated apixaban, dabigatran or rivaroxaban compared with warfarin in the United States Medicare population.
Amin A; Keshishian A; Trocio J; Dina O; Le H; Rosenblatt L; Liu X; Mardekian J; Zhang Q; Baser O; Vo L
Curr Med Res Opin; 2017 Sep; 33(9):1595-1604. PubMed ID: 28635338
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and Safety of Direct Oral Anticoagulants and Warfarin, Stratified by Stroke Risk in Patients With Atrial Fibrillation.
Hernandez I; Zhang Y; Saba S
Am J Cardiol; 2018 Jul; 122(1):69-75. PubMed ID: 29681367
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and Safety of Non-Vitamin K Antagonist Oral Anticoagulant and Warfarin in Cirrhotic Patients With Nonvalvular Atrial Fibrillation.
Lee HF; Chan YH; Chang SH; Tu HT; Chen SW; Yeh YH; Wu LS; Kuo CF; Kuo CT; See LC
J Am Heart Assoc; 2019 Mar; 8(5):e011112. PubMed ID: 30834802
[TBL] [Abstract][Full Text] [Related]
15. Frailty and Clinical Outcomes of Direct Oral Anticoagulants Versus Warfarin in Older Adults With Atrial Fibrillation : A Cohort Study.
Kim DH; Pawar A; Gagne JJ; Bessette LG; Lee H; Glynn RJ; Schneeweiss S
Ann Intern Med; 2021 Sep; 174(9):1214-1223. PubMed ID: 34280330
[TBL] [Abstract][Full Text] [Related]
16. Direct comparative effectiveness and safety between non-vitamin K antagonist oral anticoagulants for stroke prevention in nonvalvular atrial fibrillation: a systematic review and meta-analysis of observational studies.
Li G; Lip GYH; Holbrook A; Chang Y; Larsen TB; Sun X; Tang J; Mbuagbaw L; Witt DM; Crowther M; Thabane L; Levine MAH
Eur J Epidemiol; 2019 Feb; 34(2):173-190. PubMed ID: 29948370
[TBL] [Abstract][Full Text] [Related]
17. Comparative Stroke, Bleeding, and Mortality Risks in Older Medicare Patients Treated with Oral Anticoagulants for Nonvalvular Atrial Fibrillation.
Graham DJ; Baro E; Zhang R; Liao J; Wernecke M; Reichman ME; Hu M; Illoh O; Wei Y; Goulding MR; Chillarige Y; Southworth MR; MaCurdy TE; Kelman JA
Am J Med; 2019 May; 132(5):596-604.e11. PubMed ID: 30639551
[TBL] [Abstract][Full Text] [Related]
18. Direct Oral Anticoagulants Versus Vitamin K Antagonists in Real-life Patients With Atrial Fibrillation. A Systematic Review and Meta-analysis.
Escobar C; Martí-Almor J; Pérez Cabeza A; Martínez-Zapata MJ
Rev Esp Cardiol (Engl Ed); 2019 Apr; 72(4):305-316. PubMed ID: 29606361
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness and safety of rivaroxaban vs. warfarin in non-valvular atrial fibrillation patients with a non-sex-related CHA2DS2-VASc score of 1.
Coleman CI; Turpie AGG; Bunz TJ; Eriksson D; Sood NA; Baker WL
Eur Heart J Cardiovasc Pharmacother; 2019 Apr; 5(2):64-69. PubMed ID: 30020424
[TBL] [Abstract][Full Text] [Related]
20. Comparative Safety and Effectiveness of Reduced Doses of Direct Acting Oral Anticoagulants for Stroke Prevention in Atrial Fibrillation.
Skjøth F; Larsen TB; Dun AR; Lilja M; Rahman I; Abdelgawwad K; Halvorsen S; Coleman C; Rivera M
Am J Med; 2024 Jun; 137(6):520-528.e13. PubMed ID: 38387539
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]